Charite Research Organisation GmbH
Verified site
Berlin, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study involves participants with Chronic Obstructive Pulmonary Disease, a lung condition that makes it hard to breathe because the airways are narrowed and less elastic. The treatments being tested are inhaled medicines delivered as a mist: a long‑acting beta‑agonist called indacaterol, a long‑acting muscarinic antagonist called glycopyrronium bromide, and a combination of both known as AERO-007. Some participants will receive a placebo, which looks the same as the active medicine but does not contain the drug.
The purpose of the trial is to assess the bronchodilator response of each medicine after 14 days of use. Participants will take one of the inhaled options for two weeks, then switch to another option after a short break, while neither they nor the study staff know which one is being used at any time (double‑blind). Lung function will be checked with a simple breathing test that measures the amount of air expelled in one second, called FEV1, to see how well the medicines open the airways.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
11 criteria
18 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Berlin, Germany
Berlin, Germany
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an inhaled medication that belongs to a class called long‑acting beta‑agonists (LABA). It works by relaxing the muscles around the airways, which helps keep the airways open and makes breathing easier for people with COPD. In this trial participants used it alone for 14 days to see how much it improved their lung function.
is an inhaled medication that belongs to a class called long‑acting muscarinic antagonists (LAMA). It helps the lungs stay open by blocking a signal that normally tightens the airway muscles. In the study participants took this medicine by itself for 14 days to measure its effect on breathing.
is a single inhaled treatment that contains both a LABA (indacaterol) and a LAMA (glycopyrronium bromide). By combining the two different ways of relaxing airway muscles, the combination aims to provide a stronger and longer‑lasting opening of the airways than either medicine alone. Participants used this combined therapy for 14 days to see how the joint effect compared with the single‑drug treatments.
Administered by inhalation as a nebulized solution that contains no active drug, it is used only as a control in clinical studies. It has no therapeutic use and is not approved for treating any condition. Because it contains no pharmacologically active ingredient, it has no mechanism of action or drug classification.
This medication is provided as a solution for inhalation and is given to patients through a nebulizer. It is an approved long‑acting beta‑2 agonist (LABA) used to treat chronic obstructive pulmonary disease (COPD). It works by stimulating beta‑2 receptors in the airway muscles, causing them to relax and open up the airways. It is classified as a bronchodilator in the LABA drug class.
Delivered as an inhaled solution via nebulization, this drug is used to manage COPD. It is an approved long‑acting muscarinic antagonist (LAMA) that blocks muscarinic receptors, preventing airway muscles from tightening. This action helps keep the airways open and improves breathing. It belongs to the LAMA class of bronchodilators.
This combination product is a nebulized solution that contains both indacaterol and glycopyrronium bromide, and it is taken by inhalation. It is approved for the treatment of COPD and provides dual bronchodilation by both stimulating beta‑2 receptors and blocking muscarinic receptors. The two mechanisms work together to relax airway muscles more effectively than either component alone. It is classified as a combined LABA/LAMA bronchodilator therapy.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.